Delayed emesis: Moderately emetogenic chemotherapy

Fausto Roila*, David Warr, Rebecca A. Clark-Snow, Maurizio Tonato, Richard J. Gralla, Lawrence H. Einhorn, Jorn Herrstedt

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftReviewForskningpeer review


    Data on the incidence and efficacy of antiemetic prophylaxis against delayed emesis induced by moderately emetogenic chemotherapy are scanty. An overview of the literature has been done that showed the efficacy of dexamethasone in two of three randomized trials. Its optimal dose and duration of administration has not been defined. Only one of four randomized studies showed a statistically significant efficacy of 5-HT3 antagonists. Finally, only weak evidence has been published on the efficacy of dopamine receptor antagonists.

    Sider (fra-til)104-108
    Antal sider5
    TidsskriftSupportive Care in Cancer
    Udgave nummer2
    StatusUdgivet - 1 feb. 2005


    Udforsk hvilke forskningsemner 'Delayed emesis: Moderately emetogenic chemotherapy' indeholder.